GraniteShares 1.5x Long Coinbase Daily ETF

Volatility Shares Trust 2x Ether ETF

GraniteShares 1.5x Long NVDA Daily ETF

Direxion Daily TSLA Bull 1.5X Shares

ProShares Ultra Semiconductors

AXS 2X Innovation ETF

Direxion Daily Semicondct Bull 3X ETF

iShares Ethereum Trust ETF

GraniteShares 2x Long CRWD Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily Semicondct Bear 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

Bank Of Montreal

Direxion Technology Bear 3X Shares

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Tuttle Capital Short Innovation ETF

ProShares UltraPro Short QQQ

Altimmune Inc. Common Stock

HCW Biologics Inc. Common Stock

Oriental Rise Holdings Limited Ordinary Shares

Coinbase Global Inc. Class A Common Stock

First Solar Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Hims & Hers Health Inc. Class A Common Stock

Super Micro Computer Inc. Common Stock

Green Plains Inc. Common Stock

CoreWeave Inc. Class A Common Stock

TeraWulf Inc. Common Stock

Inno Holdings Inc. Common Stock

Kindly MD Inc. Common Stock

LQR House Inc. Common Stock

MicroAlgo Inc. Ordinary Shares

Siyata Mobile Inc. Common Shares

Aquestive Therapeutics Inc. Common Stock

Xenon Pharmaceuticals Inc. Common Shares

Hertz Global Holdings Inc Common Stock

Classover Holdings Inc. Class B Common Stock

UnitedHealth Group Incorporated Common Stock (DE)

Click here to get full coverage on Minerals Technologies Inc. Declares Quarterly Dividend - Stock Titan

Minerals Technologies Inc. Declares Quarterly Dividend  Stock Titan

Minerals Technologies Inc. Declares Quarterly Dividend - Stock Titan

Click here to get full coverage on Minerals Technologies Inc. Declares Quarterly Dividend | MTX Sto - GuruFocus

Minerals Technologies Inc. Declares Quarterly Dividend | MTX Sto  GuruFocus

Minerals Technologies Inc. Declares Quarterly Dividend | MTX Sto - GuruFocus

Click here to get full coverage on MTU Aero Engines (ETR:MTX) Stock Price Down 1% - Should You Sell? - MarketBeat

MTU Aero Engines (ETR:MTX) Stock Price Down 1% - Should You Sell?  MarketBeat

MTU Aero Engines (ETR:MTX) Stock Price Down 1% - Should You Sell? - MarketBeat

Click here to get full coverage on Minerals Technologies (MTX): Among the Oversold Global Stocks to Buy According to Hedge Funds - Yahoo Finance

Minerals Technologies (MTX): Among the Oversold Global Stocks to Buy According to Hedge Funds  Yahoo Finance

Minerals Technologies (MTX): Among the Oversold Global Stocks to Buy According to Hedge Funds - Yahoo Finance

Click here to get full coverage on MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025 - Pulmonary Fibrosis News

MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025  Pulmonary Fibrosis News

MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025 - Pulmonary Fibrosis News

Click here to get full coverage on PolyNovo announces TGA clearance for NovoSorb MTX and enters trading halt - Biotech Dispatch

PolyNovo announces TGA clearance for NovoSorb MTX and enters trading halt  Biotech Dispatch

PolyNovo announces TGA clearance for NovoSorb MTX and enters trading halt - Biotech Dispatch

Click here to get full coverage on Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)  PR Newswire

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire

Click here to get full coverage on A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy - Hematology Advisor

A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy  Hematology Advisor

A Case of HIV With PCNSL Refractory to MTX-Based Therapy and Immunotherapy - Hematology Advisor

Click here to get full coverage on Secretary of state spending includes millions in no-bid contracts - Indiana Capital Chronicle

Secretary of state spending includes millions in no-bid contracts  Indiana Capital Chronicle

Secretary of state spending includes millions in no-bid contracts - Indiana Capital Chronicle

Click here to get full coverage on Minerals Technologies Misses Q1 Targets, Sets $215M Talc Reserve and Unveils Strategic Cost Reduction Plan - Stock Titan

Minerals Technologies Misses Q1 Targets, Sets $215M Talc Reserve and Unveils Strategic Cost Reduction Plan  Stock Titan

Minerals Technologies Misses Q1 Targets, Sets $215M Talc Reserve and Unveils Strategic Cost Reduction Plan - Stock Titan

Click here to get full coverage on Minerals Technologies Inc (MTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance

Minerals Technologies Inc (MTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...  Yahoo Finance

Minerals Technologies Inc (MTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance

Click here to get full coverage on Northern Trust Corp Raises Stock Holdings in Minerals Technologies Inc. (NYSE:MTX) - MarketBeat

Northern Trust Corp Raises Stock Holdings in Minerals Technologies Inc. (NYSE:MTX)  MarketBeat

Northern Trust Corp Raises Stock Holdings in Minerals Technologies Inc. (NYSE:MTX) - MarketBeat

Click here to get full coverage on Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg - PR Newswire

Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg  PR Newswire

Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg - PR Newswire

Click here to get full coverage on Are Investors Undervaluing Minerals Technologies Inc. (NYSE:MTX) By 44%? - Yahoo Finance

Are Investors Undervaluing Minerals Technologies Inc. (NYSE:MTX) By 44%?  Yahoo Finance

Are Investors Undervaluing Minerals Technologies Inc. (NYSE:MTX) By 44%? - Yahoo Finance

Click here to get full coverage on Snowflake Awards MTX Group with Incentive Funding to Drive Innovation in State and Local Government - PR Newswire

Snowflake Awards MTX Group with Incentive Funding to Drive Innovation in State and Local Government  PR Newswire

Snowflake Awards MTX Group with Incentive Funding to Drive Innovation in State and Local Government - PR Newswire

Click here to get full coverage on Minerals Technologies (MTX) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance

Minerals Technologies (MTX) Misses Q1 Earnings and Revenue Estimates  Yahoo Finance

Minerals Technologies (MTX) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on MTU Aero Engines AG (ETR:MTX) Stock Goes Ex-Dividend In Just Four Days - Yahoo Finance

MTU Aero Engines AG (ETR:MTX) Stock Goes Ex-Dividend In Just Four Days  Yahoo Finance

MTU Aero Engines AG (ETR:MTX) Stock Goes Ex-Dividend In Just Four Days - Yahoo Finance

Click here to get full coverage on Here's What Key Metrics Tell Us About Minerals Technologies (MTX) Q1 Earnings - Yahoo Finance

Here's What Key Metrics Tell Us About Minerals Technologies (MTX) Q1 Earnings  Yahoo Finance

Here's What Key Metrics Tell Us About Minerals Technologies (MTX) Q1 Earnings - Yahoo Finance

Click here to get full coverage on Minerals Technologies Inc (MTX) Q4 2024 Earnings Call Highlights: Record Performance and ... - Yahoo Finance

Minerals Technologies Inc (MTX) Q4 2024 Earnings Call Highlights: Record Performance and ...  Yahoo Finance

Minerals Technologies Inc (MTX) Q4 2024 Earnings Call Highlights: Record Performance and ... - Yahoo Finance

Click here to get full coverage on Is Minerals Technologies Inc. (MTX) The Best Beaten Down Stock to Buy According to Analysts? - Yahoo Finance

Is Minerals Technologies Inc. (MTX) The Best Beaten Down Stock to Buy According to Analysts?  Yahoo Finance

Is Minerals Technologies Inc. (MTX) The Best Beaten Down Stock to Buy According to Analysts? - Yahoo Finance

Click here to get full coverage on Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress® - PR Newswire

Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress®  PR Newswire

Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress® - PR Newswire

Click here to get full coverage on Transforming the Audio Experience with MTX - MarketScale

Transforming the Audio Experience with MTX  MarketScale

Transforming the Audio Experience with MTX - MarketScale

Click here to get full coverage on Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment - Clinical Trials Arena

Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment  Clinical Trials Arena

Mediar doses first patient in Phase I trial of MTX-474 for fibrosis treatment - Clinical Trials Arena

Click here to get full coverage on Minerals Technologies Posts $4.51 Loss on Talc Reserve, But Core Business Shows Resilience with March Rebound - Stock Titan

Minerals Technologies Posts $4.51 Loss on Talc Reserve, But Core Business Shows Resilience with March Rebound  Stock Titan

Minerals Technologies Posts $4.51 Loss on Talc Reserve, But Core Business Shows Resilience with March Rebound - Stock Titan

Click here to get full coverage on Return Trends At MTU Aero Engines (ETR:MTX) Aren't Appealing - Yahoo Finance

Return Trends At MTU Aero Engines (ETR:MTX) Aren't Appealing  Yahoo Finance

Return Trends At MTU Aero Engines (ETR:MTX) Aren't Appealing - Yahoo Finance

Click here to get full coverage on HD-MTX Found Safe and Effective for Younger Patients With PCNSL - Oncology Nurse Advisor

HD-MTX Found Safe and Effective for Younger Patients With PCNSL  Oncology Nurse Advisor

HD-MTX Found Safe and Effective for Younger Patients With PCNSL - Oncology Nurse Advisor

Click here to get full coverage on Earnings Preview: Minerals Technologies (MTX) Q1 Earnings Expected to Decline - Yahoo Finance

Earnings Preview: Minerals Technologies (MTX) Q1 Earnings Expected to Decline  Yahoo Finance

Earnings Preview: Minerals Technologies (MTX) Q1 Earnings Expected to Decline - Yahoo Finance

Click here to get full coverage on Here's Why Minerals Technologies (NYSE:MTX) Has A Meaningful Debt Burden - simplywall.st

Here's Why Minerals Technologies (NYSE:MTX) Has A Meaningful Debt Burden  simplywall.st

Here's Why Minerals Technologies (NYSE:MTX) Has A Meaningful Debt Burden - simplywall.st

Click here to get full coverage on Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases - Frontiers

Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases  Frontiers

Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases - Frontiers

Click here to get full coverage on MTX stock touches 52-week low at $52.34 amid market challenges - Investing.com

MTX stock touches 52-week low at $52.34 amid market challenges  Investing.com

MTX stock touches 52-week low at $52.34 amid market challenges - Investing.com

Click here to get full coverage on Potential neurotoxicity associated with methotrexate - Nature

Potential neurotoxicity associated with methotrexate  Nature

Potential neurotoxicity associated with methotrexate - Nature

Click here to get full coverage on Minerals Technologies Q1 2025 Earnings Call: Key Details for Investors Revealed - Stock Titan

Minerals Technologies Q1 2025 Earnings Call: Key Details for Investors Revealed  Stock Titan

Minerals Technologies Q1 2025 Earnings Call: Key Details for Investors Revealed - Stock Titan

Click here to get full coverage on SynAct Pharma secures patent for resomelagon in combination with MTX - BioStock

SynAct Pharma secures patent for resomelagon in combination with MTX  BioStock

SynAct Pharma secures patent for resomelagon in combination with MTX - BioStock

Click here to get full coverage on Synthesis of MTX by the reaction between metal salt of... - ResearchGate

Synthesis of MTX by the reaction between metal salt of...  ResearchGate

Synthesis of MTX by the reaction between metal salt of... - ResearchGate

Click here to get full coverage on Lilly Makes $780M+ IPF Play with Mediar Partnership - BioSpace

Lilly Makes $780M+ IPF Play with Mediar Partnership  BioSpace

Lilly Makes $780M+ IPF Play with Mediar Partnership - BioSpace

Click here to get full coverage on Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis - PR Newswire

Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis  PR Newswire

Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis - PR Newswire

Click here to get full coverage on New Analyst Forecast: $MTX Given $92.0 Price Target - Nasdaq

New Analyst Forecast: $MTX Given $92.0 Price Target  Nasdaq

New Analyst Forecast: $MTX Given $92.0 Price Target - Nasdaq

Click here to get full coverage on Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome - Nature

Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome  Nature

Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome - Nature

Click here to get full coverage on A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Nature

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance  Nature

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Nature

Click here to get full coverage on New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance - News-Medical

New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance  News-Medical

New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance - News-Medical

Click here to get full coverage on MTX tech company opens downtown Schenectady office - The Daily Gazette

MTX tech company opens downtown Schenectady office  The Daily Gazette

MTX tech company opens downtown Schenectady office - The Daily Gazette

Click here to get full coverage on The main mechanisms of MTX toxicity in experimental disease models of... - ResearchGate

The main mechanisms of MTX toxicity in experimental disease models of...  ResearchGate

The main mechanisms of MTX toxicity in experimental disease models of... - ResearchGate

Click here to get full coverage on High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights - Frontiers

High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights  Frontiers

High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights - Frontiers

Click here to get full coverage on Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial - Nature

Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial  Nature

Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial - Nature

Click here to get full coverage on Minerals Technologies Inc. (NYSE:MTX) Q1 2025 Earnings Call Transcript - Insider Monkey

Minerals Technologies Inc. (NYSE:MTX) Q1 2025 Earnings Call Transcript  Insider Monkey

Minerals Technologies Inc. (NYSE:MTX) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on MTX Group touts return of a Capital Region office; promises jobs - Times Union

MTX Group touts return of a Capital Region office; promises jobs  Times Union

MTX Group touts return of a Capital Region office; promises jobs - Times Union

Click here to get full coverage on Mozart Therapeutics doses first patients in trial of MTX-101 for autoimmune diseases - Clinical Trials Arena

Mozart Therapeutics doses first patients in trial of MTX-101 for autoimmune diseases  Clinical Trials Arena

Mozart Therapeutics doses first patients in trial of MTX-101 for autoimmune diseases - Clinical Trials Arena

Click here to get full coverage on FTIR spectra of pure GO, graphite, FA, MTX, and MTX/FA/GO drug delivery... - ResearchGate

FTIR spectra of pure GO, graphite, FA, MTX, and MTX/FA/GO drug delivery...  ResearchGate

FTIR spectra of pure GO, graphite, FA, MTX, and MTX/FA/GO drug delivery... - ResearchGate

Click here to get full coverage on MTX Sets Aside $215M for Talc Lawsuit Trust and Chapter 11 Support | MTX Stock News - GuruFocus

MTX Sets Aside $215M for Talc Lawsuit Trust and Chapter 11 Support | MTX Stock News  GuruFocus

MTX Sets Aside $215M for Talc Lawsuit Trust and Chapter 11 Support | MTX Stock News - GuruFocus

Click here to get full coverage on "Staying MTX and advertisement free is absolutely key": Almost 20 years later, RuneScape fan turns his MMO love into an old-school RPG where fitness is the grind - GamesRadar+

"Staying MTX and advertisement free is absolutely key": Almost 20 years later, RuneScape fan turns his MMO love into an old-school RPG where fitness is the grind  GamesRadar+

"Staying MTX and advertisement free is absolutely key": Almost 20 years later, RuneScape fan turns his MMO love into an old-school RPG where fitness is the grind - GamesRadar+

Click here to get full coverage on Minerals Technologies (NYSE:MTX) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat

Minerals Technologies (NYSE:MTX) Reaches New 12-Month Low Following Analyst Downgrade  MarketBeat

Minerals Technologies (NYSE:MTX) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat

Click here to get full coverage on MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions in Preclinical Cancer Models - BioSpace

MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions in Preclinical Cancer Models  BioSpace

MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions in Preclinical Cancer Models - BioSpace

Click here to get full coverage on The 2 Best Rear Bike Racks of 2025 | Reviews by Wirecutter - The New York Times

The 2 Best Rear Bike Racks of 2025 | Reviews by Wirecutter  The New York Times

The 2 Best Rear Bike Racks of 2025 | Reviews by Wirecutter - The New York Times

Click here to get full coverage on Table 2 . The Usage of MTX in Patients Who Had a Response Number of... - ResearchGate

Table 2 . The Usage of MTX in Patients Who Had a Response Number of...  ResearchGate

Minerals Technologies Inc (MTX)

Price Chart

Key Statistics

Technicals

About MTX

Latest News

Minerals Technologies Inc. Declares Quarterly Dividend - Stock Titan

Minerals Technologies Inc. Declares Quarterly Dividend | MTX Sto - GuruFocus

MTU Aero Engines (ETR:MTX) Stock Price Down 1% - Should You Sell? - MarketBeat

Advanced Charts

Top Gainers

Top Losers